Vancomycin AUC estimates total drug exposure over 24 hours, not the amount in one sample. The usual 400–600 mg·h/L target applies principally to serious MRSA infections under specific assumptions.
- AUC24 estimates vancomycin exposure across 24 hours and is reported in mg·h/L.
- 400–600 mg·h/L is the commonly recommended AUC24 target for serious MRSA infections when the MIC is assumed to be 1 mg/L.
- AUC/MIC is an exposure-to-susceptibility ratio; AUC24 and AUC24/MIC are numerically equal only when MIC equals 1 mg/L.
- A single concentration reported in mg/L is not an AUC and cannot be compared directly with the 400–600 target.
- Muda wa sampuli must include actual infusion and collection times; conventional two-level estimation commonly uses a sample 1–2 hours after infusion ends and another near the next dose.
- Changing kidney function can invalidate yesterday’s exposure estimate, even if the prescribed dose has not changed.
- Above 600 mg·h/L generally prompts safety review rather than proving kidney injury; below 400 mg·h/L requires assessment of infection, timing, and model reliability.
- Marekebisho ya dozi belong to the prescribing team or antimicrobial pharmacist, not an online calculator or an isolated laboratory flag.
What does vancomycin AUC monitoring actually measure?
Vancomycin AUC monitoring estimates total vancomycin exposure over 24 hours, usually written AUC24 and measured in mg·h/L. For serious MRSA infections, clinicians commonly aim for 400–600 mg·h/L when the MIC is assumed to be 1 mg/L; a single concentration, sample timing, and changing kidney function must be considered before adjusting treatment.
The area under the concentration–time curve combines how high the drug concentration rises with how long it remains elevated. An AUC24 of 480 mg·h/L corresponds mathematically to an average concentration of 20 mg/L over that day, but it does not mean every sample should measure 20 mg/L.
I’m Thomas Klein, MD; the first question I ask when interpreting a vancomycin report is whether “480” means AUC24 or a concentration. A concentration of 480 mg/L would be an entirely different, potentially dangerous finding, which is why the units and the laboratory’s original wording must stay attached to every number.
Kantesti ni Mchambuzi wa mtihani wa damu wa AI that can help explain the difference between an AUC24 estimate and a measured concentration on a laboratory report. Our role is educational rather than prescriptive: the organization behind this guide cannot replace the treating team’s dosing software, medication administration record, or assessment of a patient’s current condition.
When does the vancomycin AUC target of 400–600 apply?
The vancomycin AUC target of 400–600 mg·h/L applies principally to serious invasive MRSA infections, assuming a broth-microdilution MIC of 1 mg/L. It is not a universal reference interval for every person receiving vancomycin, every organism, or every route of administration.
Rybak et al. (2020), in the joint ASHP/IDSA/PIDS/SIDP consensus guideline, recommend achieving this exposure early, preferably within 24–48 hours, for serious MRSA infections. Much of the supporting efficacy evidence comes from invasive disease, particularly complicated bloodstream infections; the authors caution against simply transferring those findings to mild infections or other bacterial species.
The denominator matters: AUC24/MIC relates exposure to the organism’s minimum inhibitory concentration. An AUC24 of 500 with an MIC of 1 gives a ratio of 500, whereas the same exposure with an MIC of 2 gives a ratio of 250; clinicians should not automatically chase an AUC24 of 800 or more to compensate.
Susceptibility methods can disagree by one doubling dilution, so an MIC of 1 versus 2 mg/L is not always a perfectly precise biological distinction. The treating team considers the testing method, clinical response, and whether another antibiotic is preferable; our explanation of matokeo ya tamaduni na uchafuzi also explains why identifying the actual pathogen comes before interpreting an exposure target.
Why is AUC different from a vancomycin trough level?
A vancomycin trough is one concentration measured near the next dose; AUC24 estimates exposure across an entire day. A trough of 15 mg/L therefore cannot be called an AUC of 15, and a trough alone does not establish whether exposure lies between 400 and 600 mg·h/L.
Historical practice often targeted troughs of 15–20 mg/L for serious MRSA infections, using them as a surrogate for adequate exposure. The 2020 consensus guideline no longer recommends trough-only targeting of that interval for serious MRSA disease because the same trough can correspond to different AUC values and unnecessarily high exposure in some patients.
Consider an illustrative pair of patients with troughs near 12 mg/L: one receives frequent smaller infusions, while the other receives larger doses farther apart. Their peaks, clearance, and curve shapes can differ enough that their AUC24 estimates fall on opposite sides of the therapeutic window; the timing of digoxin samples offers another example of why a drug number needs a dosing timeline.
A trough below 15 mg/L is not automatically treatment failure when a reliable AUC24 estimate is within target and the infection is responding. Conversely, an apparently acceptable trough does not guarantee safety; unlike the free-versus-total phenytoin distinction, the central distinction here is a snapshot versus exposure accumulated over time.
How is vancomycin AUC calculation performed?
Vancomycin AUC calculation usually uses Bayesian pharmacokinetic software or equations based on two appropriately timed concentrations. Both approaches combine measured levels with dosing information; neither calculates trustworthy 24-hour exposure from the laboratory number alone, and their assumptions should be visible to the clinician interpreting the result.
Bayesian software begins with a population pharmacokinetic model and updates its predictions using the patient’s concentrations and relevant characteristics. The guideline supports one or two concentrations for this approach, with two preferred for many circumstances; it can estimate exposure before steady state, helping teams assess the recommended 24–48-hour window rather than waiting several days.
Conventional first-order equations generally use two concentrations obtained near steady state: a post-distribution sample and a sample near the end of the dosing interval. Neely et al. (2018) evaluated Bayesian AUC-guided dosing prospectively; that evidence supports a clinical monitoring method, not the claim that any consumer calculator can accurately reconstruct exposure from one unverified result.
At steady state, a useful mathematical relationship is AUC24 = total daily dose ÷ clearance: 2,000 mg over 24 hours divided by clearance of 4 L/hour yields 500 mg·h/L. This is an explanatory example, not a dose recommendation; at Kantesti, our discussion of methodology and clinical limits should not be mistaken for validation of a patient-specific vancomycin dosing engine.
Which sample times make an AUC estimate reliable?
Reliable AUC estimation requires actual infusion start, infusion end, and sample collection times. For conventional two-level monitoring, a post-distribution concentration is commonly collected 1–2 hours after infusion ends and a trough near the next dose; local protocols and the selected Bayesian model may specify different acceptable windows.
A sample collected at 10:00 means something different if an infusion ended at 08:00 rather than 09:55. Immediately after infusion, vancomycin is still distributing between compartments, so treating that concentration as an equilibrated post-distribution level can distort an equation-based estimate; a Bayesian system must also receive the true time, not the intended time.
The actual administration record can reveal a delayed dose, an interrupted infusion, or a dose given over 2 hours instead of 1 hour. Those details reshape the predicted concentration curve even when the prescription still says the same number of milligrams; similar timestamp discipline applies to tacrolimus trough interpretation, although its therapeutic targets are entirely different.
Sampling through a line used to administer vancomycin can produce a falsely high concentration if residual drug contaminates the specimen. Staff should follow their collection protocol, and an unexpectedly extreme level may need confirmation from an appropriate site; patients should report what happened but should not disconnect lines, request a particular sampling maneuver, or alter the next infusion themselves.
How much confidence should you place in an AUC result?
An AUC24 estimate is only as credible as its input data and the suitability of its pharmacokinetic model. A reported value of 503 mg·h/L is not necessarily more certain than 500 mg·h/L, and small differences around 400 or 600 should not be interpreted without checking timing, dose history, and clinical stability.
One-level Bayesian estimation can work well when the model fits the patient and kidney function is stable, but uncertainty increases when those conditions fail. A critically ill patient with changing fluid balance may need 2 concentrations or repeat sampling even when a stable outpatient would not; software output is an estimate of physiology, not a direct measurement of the shaded area.
Ask which exposure window the report describes: the first 24 hours, the previous day, or predicted steady-state exposure on the current regimen. An AUC24 of 470 after a loading dose and a predicted maintenance AUC24 of 650 can both be correctly calculated because they answer different questions; neither should be copied into a handover without its time window.
Transcription errors deserve the same attention as pharmacokinetic uncertainty: 1,000 mg versus 100 mg, mg/L versus another unit, and collection date versus report date are not interchangeable. Our PDF transcription error checklist is relevant here because an uploaded laboratory page may omit administration details that are available only in the hospital medication record.
Why does changing kidney function alter dose decisions?
Vancomycin is cleared predominantly through the kidneys, so declining clearance can raise AUC24 without any dose increase. Recovering kidney function can do the reverse; a creatinine rise from 0.8 to 1.1 mg/dL within 48 hours may be more relevant to today’s dosing decision than yesterday’s apparently acceptable AUC.
Serum creatinine is a delayed marker when kidney function changes abruptly, and routine creatinine-based eGFR equations assume a relatively steady state. A reported eGFR of 60 mL/min/1.73 m² can therefore be misleading during evolving acute kidney injury; clinicians examine the trajectory, urine output, hemodynamics, and medication record rather than treating that estimate as a fixed drug-clearance measurement.
A creatinine increase of at least 0.3 mg/dL within 48 hours is one standard acute kidney injury criterion, even when the final value remains inside a laboratory reference interval. The different reasons BUN and creatinine rise help explain why dehydration, catabolic illness, and reduced filtration need to be separated rather than merged into one generic “kidney number.”
Kantesti ni jukwaa la tafsiri ya vipimo vya damu la AI that can place serial creatinine results in context, but laboratory trend interpretation is not real-time estimation of vancomycin clearance. Our mwongozo wa tafsiri wa BUN-kwa-kreatini provides background; an AUC24 from before a major renal change still needs reassessment by the team managing the antibiotic.
What do low, in-target, and high AUC results mean?
For serious MRSA infection with an assumed MIC of 1 mg/L, AUC24 below 400 mg·h/L may indicate insufficient exposure, 400–600 is the usual target, and above 600 warrants safety review. These categories are treatment benchmarks rather than universal normal ranges, and none independently determines whether to increase, continue, or hold a dose.
A value of 380 mg·h/L is not interpreted the same way in a patient whose infection is rapidly improving as in someone with persistent MRSA-positive cultures. The clinician first checks the estimate and intended treatment target, then considers whether inadequate exposure, an uncontrolled source, or an inappropriate antibiotic best explains the clinical picture.
An AUC24 of 620 mg·h/L does not prove toxicity, and a value of 590 does not eliminate kidney risk. The distinction between those estimates may be smaller than the uncertainty created by timing or changing clearance; our discussion of bendera za maabara zilizo nje ya kiwango explains why a flag is a prompt for interpretation rather than a diagnosis.
An unexpected AUC24 of 800 mg·h/L generally deserves prompt prescribing-team review, especially if creatinine is rising or urine output is falling. Patients should ask how quickly the result will be reviewed and which exposure window it represents, but should not assume that an automated red flag means the next dose must be skipped.
Does AUC-guided monitoring reduce kidney injury risk?
AUC-guided monitoring is intended to avoid unnecessary vancomycin exposure while maintaining antibacterial activity. Higher AUC values are associated with greater kidney injury risk, but 600 mg·h/L is a practical upper treatment boundary rather than a biological switch that separates completely safe from definitely harmful exposure.
Aljefri et al. (2019), in a Clinical Infectious Diseases meta-analysis, found an exposure–injury relationship around AUC values below versus above approximately 650 mg·h/L. The included studies used differing definitions and thresholds, so that number should not replace the guideline’s 400–600 target or be presented as an exact toxicity threshold for an individual patient.
Kidney injury can both increase vancomycin exposure and result from excessive exposure, creating a feedback loop rather than a simple one-direction association. A patient with shock, dehydration, or another nephrotoxic medicine can develop injury at an AUC24 of 500 mg·h/L; serial metabolic panel kidney clues help the team assess what else changed.
Concurrent medicines deserve review, including NSAIDs, aminoglycosides, and other treatments that may affect kidney function; patients should disclose nonprescription products rather than stopping prescribed medicines independently. A single reassuring creatinine value on day 2 does not certify that a longer course will remain safe, particularly if blood pressure, fluid balance, or the antimicrobial combination changes.
How do body size, age, and critical illness change interpretation?
Obesity, childhood, frailty, and critical illness can change vancomycin distribution or clearance and weaken assumptions behind a standard AUC estimate. The 400–600 mg·h/L target may still be used in appropriate serious MRSA settings, but the population model, sampling strategy, and monitoring frequency require particular attention.
Body weight does not translate directly into clearance: 120 kg of body mass does not automatically imply twice the maintenance requirement of 60 kg. Loading-dose decisions address initial distribution, whereas maintenance decisions address ongoing elimination; obesity-specific models and early repeat measurements help clinicians avoid confusing these two pharmacokinetic problems.
A frail older adult can have a creatinine of 0.7 mg/dL despite reduced filtration because low muscle mass limits creatinine production. A young critically ill adult can instead clear vancomycin unusually quickly; our explanation of cystatin C beyond creatinine describes why additional filtration information may sometimes help, although it does not independently supply an AUC.
My rule when explaining these cases as Thomas Klein, MD, is to separate the target from confidence in the estimate: a familiar target does not guarantee a suitable model. For children, serious MRSA guidance includes AUC-based approaches, but age-dependent clearance and the limits of adult-derived evidence matter; pediatric AI interpretation safeguards reinforce why adult dose formulas should not be reused.
Does the same approach apply to dialysis, continuous infusion, or oral vancomycin?
Dialysis, continuous IV infusion, and oral vancomycin require different monitoring assumptions. Continuous infusion can simplify AUC24 estimation once concentrations stabilize, dialysis changes clearance over time, and oral vancomycin for C. difficile generally does not use the systemic 400–600 mg·h/L target because the intended treatment site is the intestine.
For continuous infusion at a stable concentration, AUC24 equals concentration multiplied by 24 hours: 20 mg/L gives 480 mg·h/L and 25 mg/L gives 600 mg·h/L. The 2020 consensus discusses continuous-infusion concentrations around 20–25 mg/L in relevant circumstances, but that shortcut is unreliable while concentrations or renal clearance are still changing.
Intermittent hemodialysis removes vancomycin differently depending on membrane, session length, dose timing, and residual kidney function; redistribution after dialysis also complicates an immediate post-session measurement. The guideline uses predialysis concentrations of approximately 15–20 mg/L as a practical approach expected to align with target exposure in many patients, rather than treating them as directly measured AUC values.
Oral vancomycin has limited systemic absorption under usual conditions, although appreciable absorption can occur with severe intestinal disease and impaired renal clearance. Routine systemic AUC monitoring is not standard for ordinary oral treatment; our guide to discordant C. difficile test results addresses a different question—whether the intestinal illness actually warrants treatment.
How often should AUC and kidney tests be repeated?
Repeat monitoring depends on renal stability, treatment duration, and toxicity risk, not a fixed schedule for everyone. The 2020 consensus describes frequent or daily monitoring for unstable patients and approximately weekly monitoring for stable patients, with reassessment after meaningful dose, renal, or clinical changes.
Hospital discharge creates a vulnerable handover: the home infusion may begin at 09:00 rather than the hospital’s 06:00 schedule, or laboratory collection may occur after an unrecorded dose. Our explanation of laboratory changes after discharge helps distinguish physiological recovery from changes caused by medication timing and incomplete records.
A practical home-treatment plan should name who reviews each result, how the infusion times are communicated, and what happens if a sample is missed. Someone stable on day 7 may still need earlier-than-weekly reassessment after vomiting, reduced intake, fever recurrence, or a new kidney-affecting medicine; the existing schedule should never become a reason to ignore clinical deterioration.
Kantesti can help explain serial laboratory reports, but a 60-second interpretation is not a monitored antimicrobial service and should not be used to authorize the next infusion. Our mwongozo wa mwelekeo wa usalama wa dawa describes how tracking changes can support a conversation; the treating service must still review timestamps, exposure estimates, and decisions about treatment.
What should happen before a vancomycin dose is changed?
A clinician-directed dose review should verify the indication, exposure window, sample timing, renal trend, and treatment response before changing vancomycin. An AUC24 of 450 mg·h/L does not justify continuing ineffective treatment without investigation, while an unexpected estimate of 650 does not automatically tell a patient to withhold a dose.
Persistent MRSA-positive cultures despite target exposure raise questions about source control, retained devices, deeper infection, susceptibility, or the need for a different antibiotic. Increasing an AUC24 from 500 toward 600 mg·h/L cannot substitute for draining a clinically indicated collection or investigating a source that continues to release organisms; the laboratory result is only one part of the treatment assessment.
Reduced urine output, new swelling, or an unexpected creatinine rise warrants prompt contact with the treating service, even if the previous AUC24 was within range. Severe breathlessness, confusion, fainting, or rapidly worsening illness requires emergency assessment; our guide to urgent kidney-function warning signs helps distinguish a routine follow-up question from a time-sensitive problem.
Bring 5 items to the discussion: the original concentration report, actual recent dose times, infusion duration, the AUC calculation summary, and serial kidney results. I would rather see a clearly documented estimate of 520 mg·h/L with its assumptions than a screenshot saying “therapeutic”; patients should ask for explicit instructions if the next dose is due before a concerning result has been reviewed.
How can laboratory explanations support—not replace—vancomycin care?
Laboratory explanation tools can clarify units and trends, but they cannot independently authorize vancomycin dosing. Kantesti ni Zana ya uchambuzi wa vipimo vya damu inayotumia AI that can explain why AUC24 of 500 mg·h/L differs from a concentration of 20 mg/L; our taarifa za faragha na data also matters when sharing medication-linked reports.
A useful explanation should identify at least 3 limits: missing administration records, uncertainty about the calculated exposure window, and kidney function that may have changed since sampling. Our habari za ushauri wa kimatibabu describes the medical team; a public article or advisory listing does not mean that an individual patient’s AUC calculation has been reviewed or approved.
The related Figshare publication “B Negative Blood Type, LDH Blood Test & Reticulocyte Count Guide” belongs to broader laboratory education, not antibiotic pharmacokinetic evidence. The accompanying hematology interpretation background can support understanding of additional tests, but neither publication establishes the vancomycin 400–600 mg·h/L target or validates a dosing method.
The second listed Figshare publication, “Diarrhea After Fasting, Black Specks in Stool & GI Guide 2026,” addresses gastrointestinal interpretation rather than systemic vancomycin exposure. Our tafsiri ya dalili za mfumo wa mmeng'enyo is related educational reading; it should not be used to diagnose C. difficile or decide whether oral or IV antibiotics are needed.
As of October 14, 2026, this article’s main dosing benchmark is attributed to the 2020 multidisciplinary consensus guideline, not to a newly claimed 2026 guideline. The 2 Figshare records below are supplied as supplementary publications with title-first citations because author and publication-date metadata were not provided; discovery links are searches, not verified mirrored publications.
Maswali Yanayoulizwa Mara Kwa Mara
0 Maana ya vancomycin AUC 400–600 ni nini?
AUC ya Vancomycin ya 400–600 kwa kawaida humaanisha mfiduo uliokadiriwa wa saa 24 wa 400–600 mg·h/L kwa maambukizi makali ya MRSA, ikichukuliwa kuwa MIC ni 1 mg/L. AUC huunganisha mkusanyiko wa dawa na muda, badala ya kueleza sampuli moja ya maabara. Lengo hili si kiwango cha kawaida cha jumla kwa kila maambukizi au njia ya utoaji wa dawa. Daktari anayekutibu lazima alitafsiri pamoja na muda wa kuchukuliwa kwa sampuli, utendaji kazi wa figo na mwitikio wa matibabu.
Je, kiwango cha chini kabisa cha vancomycin cha 10–15 mg/L ni cha chini mno?
Kiwango cha chini kabisa cha vancomycin cha 10–15 mg/L si lazima kiwe cha chini kupita kiasi ikiwa makadirio ya kuaminika ya AUC24 yanafikia lengo linalofaa. Baadhi ya wagonjwa hufikia AUC24 ya 400–600 mg·h/L bila kiwango cha chini kabisa cha 15–20 mg/L. Kiwango cha chini kabisa pekee hakiwezi kuthibitisha kwa uhakika mfiduo wa jumla kwa kila mgonjwa. Maamuzi kuhusu dozi yanapaswa kuzingatia sababu ya kliniki, mbinu iliyothibitishwa ya ufuatiliaji, na utendaji wa sasa wa figo.
Je, AUC ya vancomycin inaweza kuhesabiwa kutokana na kipimo kimoja cha kiwango chake?
0 Vancomycin AUC inaweza wakati mwingine kukadiriwa kutokana na kipimo kimoja cha ukolezi kwa kutumia programu inayofaa ya kifamasia ya Bayesian na historia sahihi ya utoaji wa dozi. Mwongozo wa makubaliano wa mwaka 2020 unaunga mkono kutumia kipimo kimoja au viwili vya ukolezi kwa ukadiriaji wa Bayesian, huku vipimo viwili vikipendelewa katika hali nyingi. Ukadiriaji wa kawaida unaotegemea milinganyo kwa ujumla huhitaji vipimo viwili vya ukolezi vilivyochukuliwa kwa muda unaofaa karibu na hali ya uthabiti. Namba moja ya maabara bila nyakati za utoaji wa dawa na ukusanyaji wa sampuli si msingi wa kuaminika wa kukokotoa AUC.
Je, AUC ya vancomycin iliyo juu ya 600 inamaanisha uharibifu wa figo?
AUC24 ya vancomycin iliyo juu ya 600 mg·h/L huashiria mfiduo ulio juu ya lengo la kawaida kwa MRSA kali, lakini haithibitishi uharibifu wa figo. Mfiduo wa juu zaidi unahusishwa na hatari kubwa zaidi ya jeraha la figo, na tafsiri hutegemea mwelekeo wa utendaji wa figo, dawa nyingine na usahihi wa makadirio. Ongezeko la creatinine la angalau 0.3 mg/dL ndani ya saa 48 ni mojawapo ya vigezo vya kawaida vya jeraha la ghafla la figo. Wasiliana na timu inayokutibu mara moja badala ya kuruka au kubadilisha dozi mwenyewe.
Sampuli za vancomycin zinapaswa kukusanywa lini kwa ajili ya ufuatiliaji wa AUC?
Ufuatiliaji wa kawaida wa AUC ya vancomycin kwa kutumia viwango viwili mara nyingi hutumia sampuli ya baada ya usambazaji inayochukuliwa saa 1–2 baada ya mwisho wa uwekaji wa dawa kwa njia ya mshipa, na sampuli ya kiwango cha chini karibu na dozi inayofuata. Itifaki za Bayesian zinaweza kuruhusu nyakati nyingine za ukusanyaji, kutegemea modeli na utaratibu wa eneo husika. Nyakati halisi za uwekaji wa dawa na ukusanyaji wa sampuli lazima zirekodiwe kwa sababu nyakati zilizopangwa zinaweza kutofautiana na zilizotokea. Fuata maelekezo ya huduma inayomtibu mgonjwa badala ya kujichagulia nyakati za ukusanyaji wa sampuli.
Does oral vancomycin need AUC monitoring?
Routine AUC monitoring is generally not required for oral vancomycin used to treat C. difficile because systemic absorption is usually limited. The 400–600 mg·h/L systemic target is not the ordinary treatment goal for an antibiotic acting mainly in the intestine. Severe intestinal disease and impaired kidney clearance can occasionally produce appreciable systemic absorption. A clinician may request concentrations in selected high-risk circumstances rather than applying routine IV monitoring to every oral course.
Pata Uchambuzi wa Vipimo vya Damu kwa AI Leo
Jiunge na zaidi ya watumiaji 2 milioni duniani kote wanaoamini Kantesti kwa uchambuzi wa papo hapo na sahihi wa vipimo vya maabara. Pakia matokeo yako ya vipimo vya damu na upate tafsiri ya kina ya viashiria vya 15,000+ ndani ya sekunde.
📚 Machapisho ya Utafiti Yanayorejelewa
Klein, T., Mitchell, S., & Weber, H. (2026). Mwili wa damu Aina ya B Negativu, Mwongozo wa Kipimo cha Damu cha LDH na Hesabu ya Reticulocyte. Kantesti uchambuzi wa damu kwa AI ya utafiti wa matibabu.
Klein, T., Mitchell, S., & Weber, H. (2026). Kuhara Baada ya Kufunga, Madoa Meusi kwenye Kinyesi na Mwongozo wa GI 2026. Kantesti uchambuzi wa damu kwa AI ya utafiti wa matibabu.
📖 Marejeo ya Nje ya Tiba
Rybak MJ et al. (2020). Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. American Journal of Health-System Pharmacy.
Neely MN et al. (2018). Prospective Trial on the Use of Trough Concentration versus Area under the Curve To Determine Therapeutic Vancomycin Dosing. Antimicrobial Agents and Chemotherapy.
Aljefri DM et al. (2019). Vancomycin Area Under the Curve and Acute Kidney Injury: A Meta-analysis. Clinical Infectious Diseases.
⚕️ Kanusho la Kimatibabu
Makala haya ni kwa madhumuni ya elimu tu na si ushauri wa kimatibabu. Wasiliana na mtoa huduma aliyehitimu kila wakati kwa maamuzi ya utambuzi na matibabu.
E-E-A-T Trust Signals
Uzoefu
Mapitio ya kimatibabu inayoongozwa na daktari ya mifumo ya tafsiri ya maabara.
Utaalamu
Kuzingatia dawa za maabara kuhusu jinsi viashiria (biomarkers) vinavyobadilika katika muktadha wa kliniki.
Mamlaka
Imeandikwa na Dk. Thomas Klein kwa mapitio ya Dk. Sarah Mitchell na Prof. Dk. Hans Weber.
Uaminifu
Tafsiri inayotegemea ushahidi yenye njia zilizo wazi za ufuatiliaji ili kupunguza tahadhari za hofu.